1-20 of 53
Aaron D Goldberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study

Shai Shimony, Jan Philipp Bewersdorf, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, Evan C. Chen, Jorge Ramos, R. Coleman Lindsley, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl
Journal: Blood
Blood (2023) 142 (Supplement 1): 1478.
https://doi.org/10.1182/blood-2023-172763
Published: 2023
Journal Articles

A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation

Lindsey E. Roeker, Andrew D. Zelenetz, Jae H. Park, Andriy Derkach, Mark Blaine Geyer, Prioty Islam, Lorenzo Falchi, Maria Lia Palomba, Anita Kumar, Gilles Salles, Jennifer Kimberly Lue, Aaron D. Goldberg, Bita Fakhri, Catherine C. Coombs, Victoria Falco, Gail Panton, Dianna Tyznar, Dhara Soni, Lauren Nogan, Sonia Lebowitz, Katherine Blesie, Monica Shah, Sarah Court, Christopher E. Jensen, Anthony R. Mato, Meghan C. Thompson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4657.
https://doi.org/10.1182/blood-2023-181661
Published: 2023
Journal Articles

Comparative Analysis of Clinical Outcomes and Healthcare Resource Utilization (HRU) in Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Unfit for High-Intensity Chemotherapy Treated with Venetoclax (VEN) Vs Other Therapies: Results from the AML Real World Evidence (ARC) Initiative

Pinkal Desai, Jacqueline S. Garcia, Joshua F. Zeidner, Sameem Abedin, Ofir Wolach, Pankit Vachhani, Yakir Moshe, Daniel A. Pollyea, Catherine Lai, Thomas W LeBlanc, Marin Xavier, Boaz Nachmias, Evan C. Chen, Srilakshmi Bathini, Inderpreet Bhatti, Cat N. Bui, Annie Guérin, Rebecca Burne, Esprit Ma, Moshe Grunspan, Neta Frankel, Aaron D. Goldberg
Journal: Blood
Blood (2023) 142 (Supplement 1): 5173.
https://doi.org/10.1182/blood-2023-173283
Published: 2023
Journal Articles

Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in IDH1- or IDH2 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl
Journal: Blood
Blood (2023) 142 (Supplement 1): 1589.
https://doi.org/10.1182/blood-2023-174283
Published: 2023
Journal Articles

Comparable Survival of Treatment Naïve TP53 Mutated Acute Myeloid Leukemia Treated with Hypomethylating Agent Compared to Hypomethylating Agent Plus Venetoclax Based Therapy

Talha Badar, Ehab L. Atallah, Rory M. Shallis, Anand Ashwin Patel, Guilherme Sacchi De Camargo Correia, Aaron D. Goldberg, Antoine Saliba, Jan Philipp Bewersdorf, Adam S Duvall, Danielle Bradshaw, Yasmin Abaza, Guru Subramanian Guru Murthy, Neil Palmisiano, Vamsi K. Kota, Mark R. Litzow
Journal: Blood
Blood (2023) 142 (Supplement 1): 592.
https://doi.org/10.1182/blood-2023-184626
Published: 2023
Journal Articles

A Phase 1a/b Trial of Luxeptinib (CG-806) in Patients with Relapsed/Refractory B-Cell Malignancies or Acute Myeloid Leukemia and Evaluation of New G3 Formulation

Aaron D. Goldberg, Felipe Samaniego, Maro Ohanian, Paul B. Koller, Namrata Sonia Chandhok, Ahad A. Sadiq, Daruka Mahadevan, Mohamad A. Cherry, Jessica K. Altman, John M. Burke, Michael Z. Koontz, J. C. C Villasboas, Ben K. Tomlinson, Laura E. Finn, Erin G Reid, Jason Melear, Victor Priego, Patrick Cobb, Elizabeth Heritage Cull, Paul Conkling, David Cosgrove, Lindsey E. Roeker, Eric Tam, Donna Nguyen Haney, Jia Hu, Ranjeet Sinha, Nawazish Khan, William G. Rice, Rafael Bejar
Journal: Blood
Blood (2023) 142 (Supplement 1): 5953.
https://doi.org/10.1182/blood-2023-181151
Published: 2023
Journal Articles

Despite High Rates of Remission, Treatment of IDH-Mutant AML with Hypomethylating Agents and Venetoclax Is Associated with Frequent Treatment Delays, Modifications, and Transfusions

Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav Gupta, Prabhakar Borge, Ellin Berman, Mark Blaine Geyer, Aaron D. Goldberg, Tamanna Haque, Raajit K. Rampal, Jae H. Park, Lindsey E. Roeker, Martin S. Tallman, Eytan M. Stein
Journal: Blood
Blood (2023) 142 (Supplement 1): 1519.
https://doi.org/10.1182/blood-2023-182012
Published: 2023
Journal Articles

Intensive Induction Chemotherapy Vs Hypomethylating Agents + Venetoclax (HMA/VEN) in NPM1 -Mutant Newly Diagnosed Acute Myeloid Leukemia (AML) - a Multicenter Cohort Study

Jan Philipp Bewersdorf, Shai Shimony, Rory M. Shallis, Yiwen Liu, Eva Johanna Schaefer, Amer M. Zeidan, Aaron D. Goldberg, Eytan M. Stein, Guido Marcucci, R. Coleman Lindsley, Evan C. Chen, Jorge Ramos, Anthony Selwyn Stein, Daniel J. DeAngelo, Donna S. Neuberg, Richard M Stone, Brian J. Ball, Maximilian Stahl
Journal: Blood
Blood (2023) 142 (Supplement 1): 2964.
https://doi.org/10.1182/blood-2023-174285
Published: 2023
Journal Articles

Komet-008: A Phase 1 Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-Rearranged or NPM1-Mutant Relapsed/Refractory Acute Myeloid Leukemia

Aaron D. Goldberg, Daniel Corum, Julie Ahsan, Kun Nie, Tom Kozlek, Mollie Leoni, Stephen Dale
Journal: Blood
Blood (2023) 142 (Supplement 1): 1553.
https://doi.org/10.1182/blood-2023-190475
Published: 2023
Journal Articles

TP53 Y220C Mutations in Patients with Myeloid Malignancies

Georgina Gener-Ricos, Jan Philipp Bewersdorf, Sanam Loghavi, Aaron D. Goldberg, Christopher Famulare, Ghayas C. Issa, Gautam Borthakur, Tapan M. Kadia, Bing Z. Carter, Keyur P. Patel, Michael Andreeff, Eytan M. Stein, Courtney D. DiNardo
Journal: Blood
Blood (2023) 142 (Supplement 1): 1477.
https://doi.org/10.1182/blood-2023-189343
Published: 2023
Journal Articles

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Clinical Trials & Observations
Amanda Przespolewski, Aaron D. Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang
Journal: Blood
Blood (2023) 141 (12): 1489–1493.
https://doi.org/10.1182/blood.2022016678
Published: 2023
Includes: Supplemental data
Journal Articles

Single Cell Genotypic and Phenotypic Analysis of Measurable Residual Disease in Acute Myeloid Leukemia

Troy Robinson, Robert L. Bowman, Sonali Persaud, Ying Liu, Qi Gao, Jing-Ping Zhang, Xiaotian Sun, Adam Sciambi, Aaron Llanso, Christopher Famulare, Aaron D Goldberg, Ahmet Dogan, Mikhail Roshal, Ross L. Levine, Wenbin Xiao
Journal: Blood
Blood (2022) 140 (Supplement 1): 2275–2277.
https://doi.org/10.1182/blood-2022-166501
Published: 2022
Journal Articles

Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITD high but Not FLT3-ITD low and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age

Eric S. Winer, Yael Flamand, Rory Michael Shallis, Jessica M. Stempel, Aaron D Goldberg, Maximilian F. Stahl, Anand Ashwin Patel, Adam S Duvall, Yasmin Abaza, Timothy Seijung Oh, Karen Ma, Talha Badar, Mark R. Litzow, Vamsi Kota, Danielle Bradshaw, Hari S. Raman, Marlise R. Luskin, Richard M. Stone, Daniel J. DeAngelo
Journal: Blood
Blood (2022) 140 (Supplement 1): 6285–6287.
https://doi.org/10.1182/blood-2022-170587
Published: 2022
Journal Articles

Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Ofir Wolach, Jacqueline S. Garcia, Pinkal Desai, Pankit Vachhani, Joshua F. Zeidner, Sameem Abedin, Kendra Sweet, Catherine Lai, Yakir Moshe, Daniel A. Pollyea, Marin Xavier, Boaz Nachmias, Tsila Zuckerman, Sangmin Lee, Evan C. Chen, Srilakshmi Bathini, Wesleigh Edwards, Cat N. Bui, Wei-Han Cheng, Catherine Miller, Annie Guerin, Jessica Maitland, Esprit Ma, Melissa Montez, Moshe Grunspan, Aaron D Goldberg
Journal: Blood
Blood (2022) 140 (Supplement 1): 11026–11028.
https://doi.org/10.1182/blood-2022-159615
Published: 2022
Journal Articles

Quantitative Cytogenetic Analysis with karyoParser Allows for More Precise Identification of Disease Biology, Clonal Evolution, and Etiology of Relapse in Acute Myeloid Leukemia

Deepika Dilip, Andriy Derkach, Kamal Menghrajani, Aaron D Goldberg, Hannah May, Virginia M. Klimek, Pallavi K Galera, Wenbin Xiao, Yanming Zhang, Olivier Elemento, Ross L. Levine, Jacob L Glass
Journal: Blood
Blood (2022) 140 (Supplement 1): 9119–9121.
https://doi.org/10.1182/blood-2022-170847
Published: 2022
Journal Articles

Clinical Outcomes of Patients with TP53 -Mutated AML after First Relapse or with Primary Refractory Disease: Results from Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Antoine N. Saliba, Rory Michael Shallis, Maximilian F. Stahl, Jan Philipp Bewersdorf, Guillerhme Sacchi De Camargo Correia, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Danielle Bradshaw, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow
Journal: Blood
Blood (2022) 140 (Supplement 1): 6058–6060.
https://doi.org/10.1182/blood-2022-163795
Published: 2022
Journal Articles

A Phase 1a/b Dose Escalation Study of the FLT3/BTK Inhibitor Luxeptinib (CG-806) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Aaron D Goldberg, Maro Ohanian, Paul B. Koller, Mohamad Cherry, Jessica K. Altman, Benjamin Tomlinson, Namrata Sonia Chandhok, Donna Nguyen Haney, Jia Hu, Ranjeet Kumar Sinha, William G Rice, Rafael Bejar
Journal: Blood
Blood (2022) 140 (Supplement 1): 6220–6221.
https://doi.org/10.1182/blood-2022-167759
Published: 2022
Journal Articles

Predictors of Long-Term Outcome in TP53 -Mutated Acute Myeloid Leukemia Patients Receiving Allogeneic Stem Cell Transplant after First- or Second-Line Therapy: Results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab L. Atallah, Rory Michael Shallis, Antoine N. Saliba, Maximilian F. Stahl, Jan Philipp Bewersdorf, Justin Grenet, Anand Ashwin Patel, Yasmin Abaza, Guru Subramanian Guru Murthy, Adam S Duvall, Madelyn Burkart, Neil Palmisiano, Michal Jakub Kubiak, Vamsi K. Kota, Shira Dinner, Aaron D Goldberg, Mark R. Litzow
Journal: Blood
Blood (2022) 140 (Supplement 1): 1435–1437.
https://doi.org/10.1182/blood-2022-167731
Published: 2022
Journal Articles

Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia

Justin Grenet, Akriti G Jain, Madelyn Burkart, Julian Waksal, Christopher Famulare, Yazan Numan, Maximilian Stahl, Zoe Mckinnell, Brian Ball, Xiaoyue Ma, Paul J Christos, Ellen Ritchie, Michael B. Samuel, Justin D. Kaner, Sangmin Lee, Aaron D Goldberg, Shira Dinner, Kendra Sweet, Gail J. Roboz, Pinkal Desai
Journal: Blood
Blood (2021) 138 (Supplement 1): 32.
https://doi.org/10.1182/blood-2021-145947
Published: 2021
Journal Articles

Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53 -Mutant Acute Myeloid Leukemia (AML)

Guillermo Garcia-Manero, Aaron D Goldberg, Eric S. Winer, Jessica K. Altman, Amir T. Fathi, Olatoyosi Odenike, Gail J. Roboz, Phillip Gallacher, Anders Wennborg, Denice Kaylor Hickman, Eyal C. Attar, David A. Sallman
Journal: Blood
Blood (2021) 138 (Supplement 1): 3409.
https://doi.org/10.1182/blood-2021-148940
Published: 2021